Use of acridine orange in: flow cytometric assessment of micronuclei induction

被引：34

作者：

Criswell, KA ^{[1
]}

Krishna, G ^{[1
]}

Zielinski, D ^{[1
]}

Urda, GA ^{[1
]}

Theiss, JC ^{[1
]}

Juneau, P ^{[1
]}

Bleavins, MR ^{[1
]}

机构：

[1] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Pathol & Expt Toxicol, Ann Arbor, MI 48105 USA

来源：

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS | 1998年 / 414卷 / 1-3期

关键词：

MN; micronucleus; acridine orange; flow cytometry; cyclophosphamide;

D O I：

10.1016/S1383-5718(98)00042-4

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The micronucleus assay is a widely accepted method for evaluation of clastogens and aneugens. In the current study, acridine orange (AO) supravital staining was adapted for flow cytometric usage to assess micronucleated cells in rat bone marrow and spleen. Cyclophosphamide was used as a positive control test compound and results were compared to manual scoring in Wright-stained slides. In bone marrow, both manual and flow cytometric methods demonstrated positive dose response-trends for micronucleated polychromatic erythrocytes (MNPCE). Significant elevations in MNPCE were observed at all doses of cyclophosphamide, and comparisons between methods in bone marrow were not statistically different. The flow cytometric method was more sensitive in spleen samples, showing dose-and time-related increases in micronuclei compared with manual scoring. AO proved to be a sensitive discriminator of RNA and DNA, allowing distinct separation of polychromatic erythrocytes (PCE), normochromic erythrocytes (NCE), total nucleated cells (TNC), and micronucleated populations within both PCE and NCE regions. These results support the use of AO-based flow cytometry to provide a rapid and sensitive indicator of micronuclei inducers or non-inducers. (C) 1998 Elsevier Science B.V. All rights reserved.

引用

页码：63 / 75

页数：13

共 30 条

[1]

[Anonymous], 1986, MUTAT RES

[2] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].